| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 04/24/2003 | WO2003033699A2 Production, detection and use of transformant cells |
| 04/24/2003 | WO2003033698A1 Method for unspecific enrichment of bacteria cells |
| 04/24/2003 | WO2003033697A1 Conversion of liver stem and progenitor cells to pancreatic functional cells |
| 04/24/2003 | WO2003033696A1 Vegf antisense compound |
| 04/24/2003 | WO2003033695A1 Method of purifying recombinant fused protein and method of producing protein using the same |
| 04/24/2003 | WO2003033692A2 Use of the adenoviral e2 late promoter |
| 04/24/2003 | WO2003033689A1 Cloning and recombinant expression of mammalian secreted group iif phopholipase a2 |
| 04/24/2003 | WO2003033688A1 Regulation of human receptor tyrosine phosphatase |
| 04/24/2003 | WO2003033685A2 Method of producing human beta cell lines |
| 04/24/2003 | WO2003033682A1 Dna fpr expression of alpha i-antitrypsin in methylotropic yeast |
| 04/24/2003 | WO2003033680A2 Kinases and phosphatases |
| 04/24/2003 | WO2003033677A2 Dimerized growth factor and materials and methods for producing it |
| 04/24/2003 | WO2003033674A2 Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 04/24/2003 | WO2003033673A2 High-throughput transcriptome and functional validation analysis |
| 04/24/2003 | WO2003033672A2 Nr3b nmda receptor subunit compositions and related methods |
| 04/24/2003 | WO2003033670A2 Method for preparation of single chain antibodies |
| 04/24/2003 | WO2003033664A2 Bone anti-resorptive compounds |
| 04/24/2003 | WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 04/24/2003 | WO2003033659A2 Antisense modulation of matrix metalloproteinase 1 expression |
| 04/24/2003 | WO2003033657A2 Antisense antiviral agent and method for treating ssrna viral infection |
| 04/24/2003 | WO2003033654A2 Direct targeting binding proteins |
| 04/24/2003 | WO2003033653A2 Affinity enhancement agents |
| 04/24/2003 | WO2003033651A2 Compositions and methods for promoting nematode resistance in plants |
| 04/24/2003 | WO2003033646A2 Compositions and methods for the modulation of viral maturation |
| 04/24/2003 | WO2003033643A2 Three dimensional crystal structure of human sorbitol dehydrogenase and uses thereof |
| 04/24/2003 | WO2003033540A2 Starch |
| 04/24/2003 | WO2003033538A1 Anti-hla-dr antibody |
| 04/24/2003 | WO2003033534A2 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof |
| 04/24/2003 | WO2003033532A1 Anitmicrobial proteins, genes encoding the proteins and mehtod of using the same |
| 04/24/2003 | WO2003033530A2 Mycobacterial antigens expressed under high oxygen tension |
| 04/24/2003 | WO2003033522A1 Isolation of lectins |
| 04/24/2003 | WO2003033521A1 Inppressor trna system in mammalian cells for the introduction of unnatural amino acids in polypeptides. |
| 04/24/2003 | WO2003033519A2 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
| 04/24/2003 | WO2003033514A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 04/24/2003 | WO2003033513A1 Differentially expressed genes associated with obesity and type 2 diabetes |
| 04/24/2003 | WO2003033029A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | WO2003032925A2 Glycosulfopeptide inhibitors and methods of use thereof |
| 04/24/2003 | WO2003032923A2 Induction of beta cell differentiation in human cells |
| 04/24/2003 | WO2003032920A2 Oligonucleotide modulation of cell adhesion |
| 04/24/2003 | WO2003032913A2 Methods and compositions for targeting proteins across the blood brain barrier |
| 04/24/2003 | WO2003032898A2 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | WO2003032813A2 Methods for the treatment of carcinoma |
| 04/24/2003 | WO2003032810A2 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | WO2003032809A2 Modulation of akt-dependent response to prevent restenosis |
| 04/24/2003 | WO2003032727A1 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| 04/24/2003 | WO2003032713A2 COFFEE PLANT WITH REDUCED α-D-GALACTOSIDASE ACTIVITY |
| 04/24/2003 | WO2003011887A3 Antisense modulation of apolipoprotein b expression |
| 04/24/2003 | WO2003006643A3 A p387l variant in protein tyrosine phosphatase-1b is associated with type 2 diabetes and impaired serine phosphorylation of ptp-1b in vitro |
| 04/24/2003 | WO2003005964A3 Recombinant vsv for the treatment of tumor cells |
| 04/24/2003 | WO2003004699A3 Method for identifying nucleic acid molecules amplified in a polymerase chain reaction |
| 04/24/2003 | WO2003004631A3 USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |
| 04/24/2003 | WO2002099064A3 Rna purification methods |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002098457A3 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
| 04/24/2003 | WO2002095016A3 Champ - a cardiac helicase-like factor |
| 04/24/2003 | WO2002088343A3 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) |
| 04/24/2003 | WO2002088180A3 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 04/24/2003 | WO2002085295A3 Methods and compositions for the modulation of biofilm formation |
| 04/24/2003 | WO2002085094A3 Transgenic mice containing acylphosphatase gene disruptions |
| 04/24/2003 | WO2002079432A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/24/2003 | WO2002079429A3 Anti-muc-1 single chain antibodies for tumor targeting |
| 04/24/2003 | WO2002079422A3 Transgenic mice containing novel poz domain gene disruptions |
| 04/24/2003 | WO2002079420A3 Adam-like protease disruptions, compositions and methods related thereto |
| 04/24/2003 | WO2002079412A3 Transgenic mice containing usp3-like deubiquitinating enzyme gene disruptions |
| 04/24/2003 | WO2002074959A3 Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1 |
| 04/24/2003 | WO2002072822A3 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 04/24/2003 | WO2002066507A3 Histidine phosphatase interacting protein of 120 kd |
| 04/24/2003 | WO2002064817A3 Use of bacteria in a method for producing cellulose |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002063000A9 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same |
| 04/24/2003 | WO2002061039A3 Thuja plicata dirigent protein promotors |
| 04/24/2003 | WO2002060938A3 Haemophilus influenza basb212 polynucleotides, polypeptides and use thereof |
| 04/24/2003 | WO2002059298A9 Gab2(p97) gene and methods of use thereof |
| 04/24/2003 | WO2002057483A3 Method of identifying modulators of nogo-functions |
| 04/24/2003 | WO2002056900A3 Use of slpi for treating chronic inflammatory intestinal diseases |
| 04/24/2003 | WO2002055717A3 Enhanced secretion of a polypeptide by a microorganism |
| 04/24/2003 | WO2002055707A3 Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen |
| 04/24/2003 | WO2002052029A9 Process for producing recombinant protein and fused protein |
| 04/24/2003 | WO2002051988A3 Thymic epithelial progenitor cells and uses thereof |
| 04/24/2003 | WO2002051870A3 Phage display libraries of human vh fragments |
| 04/24/2003 | WO2002050295A3 Arcelin-5 promoter and uses thereof |
| 04/24/2003 | WO2002050120A3 High affinity antibodies |
| 04/24/2003 | WO2002050094A3 Nucleic acid synthesis by primer extension on successive templates |
| 04/24/2003 | WO2002049576A9 Fab i and inhibition of apicomplexan parasites |
| 04/24/2003 | WO2002048367A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/24/2003 | WO2002048344A3 Gene therapy for prostate cancer: sensibilization of cells to dn a damaging drugs and radiation |
| 04/24/2003 | WO2002048332A9 Recombinant phytases and uses thereof |
| 04/24/2003 | WO2002046383A3 Protein modification and maintenance molecules |
| 04/24/2003 | WO2002046366A9 Rf2a and rf2b transcription factors |
| 04/24/2003 | WO2002046227A3 Glp-1 fusion proteins |
| 04/24/2003 | WO2002045500A3 Transgenic mice containing ptp36 tyrosine phosphatase disruptions |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002043741A3 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 04/24/2003 | WO2002042733A9 Method for analyzing mass spectra |
| 04/24/2003 | WO2002040688A3 Maize yellow stripe1 and related genes |
| 04/24/2003 | WO2002038171A3 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 04/24/2003 | WO2002030980A3 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 04/24/2003 | WO2002026825A3 G-protein coupled receptors |
| 04/24/2003 | WO2002020651A3 Human phermone polypeptide |
| 04/24/2003 | WO2002018585A8 Packaging of positive-strand rna virus replicon particles |